BACKGROUND: Treating asthmatics with the humanized IgE-scavenging antibody, omalizumab (rhuMAb-E25, Xolair, reduces airways inflammation and asthma symptoms. Previously, omalizumab was shown to cause a dramatic and reversible loss of cell surface high-affinity IgE receptors, FcepsilonRI, from the peripheral blood basophils of asthmatics. The consequences of receptor loss for the FcepsilonRI-mediated synthesis and release of cytokines implicated in allergic asthma have not been examined. METHODS: Fifteen asthmatic volunteers each received omalizumab for 12 weeks. Peripheral blood basophils were isolated before, during, 2 weeks after and 6 months after omalizumab. Basophils were assayed for the basal and anti-IgE-stimulated release of cytokines, chemokines and histamine. Pooled data were analyzed by repeated measures ANOVA and by paired t tests. RESULTS: Anti-IgE-stimulated human basophils synthesize and release Th2 cytokines (IL-4, IL-13) and chemokines (IL-8, RANTES). The anti-IgE-stimulated release of IL-4, IL-13 and IL-8 was reduced during omalizumab treatment and returned to pretreatment levels after omalizumab withdrawal. Omalizumab did not alter basophil histamine levels or basal and anti-IgE-stimulated histamine release. CONCLUSIONS: Omalizumab may reduce asthma symptoms in part by suppressing the FcepsilonRI-mediated production by basophils of Th2 cytokines and selected chemokines. Anti-IgE-stimulated basophil cytokine synthesis appears more sensitive than histamine release to the loss of FcepsilonRI caused by omalizumab treatment. 2009 S. Karger AG, Basel.
BACKGROUND: Treating asthmatics with the humanized IgE-scavenging antibody, omalizumab (rhuMAb-E25, Xolair, reduces airways inflammation and asthma symptoms. Previously, omalizumab was shown to cause a dramatic and reversible loss of cell surface high-affinity IgE receptors, FcepsilonRI, from the peripheral blood basophils of asthmatics. The consequences of receptor loss for the FcepsilonRI-mediated synthesis and release of cytokines implicated in allergic asthma have not been examined. METHODS: Fifteen asthmatic volunteers each received omalizumab for 12 weeks. Peripheral blood basophils were isolated before, during, 2 weeks after and 6 months after omalizumab. Basophils were assayed for the basal and anti-IgE-stimulated release of cytokines, chemokines and histamine. Pooled data were analyzed by repeated measures ANOVA and by paired t tests. RESULTS: Anti-IgE-stimulated human basophils synthesize and release Th2 cytokines (IL-4, IL-13) and chemokines (IL-8, RANTES). The anti-IgE-stimulated release of IL-4, IL-13 and IL-8 was reduced during omalizumab treatment and returned to pretreatment levels after omalizumab withdrawal. Omalizumab did not alter basophil histamine levels or basal and anti-IgE-stimulated histamine release. CONCLUSIONS:Omalizumab may reduce asthma symptoms in part by suppressing the FcepsilonRI-mediated production by basophils of Th2 cytokines and selected chemokines. Anti-IgE-stimulated basophil cytokine synthesis appears more sensitive than histamine release to the loss of FcepsilonRI caused by omalizumab treatment. 2009 S. Karger AG, Basel.
Authors: M Solèr; J Matz; R Townley; R Buhl; J O'Brien; H Fox; J Thirlwell; N Gupta; G Della Cioppa Journal: Eur Respir J Date: 2001-08 Impact factor: 16.671
Authors: W Busse; J Corren; B Q Lanier; M McAlary; A Fowler-Taylor; G D Cioppa; A van As; N Gupta Journal: J Allergy Clin Immunol Date: 2001-08 Impact factor: 10.793
Authors: K T Nouri-Aria; A M Irani; M R Jacobson; F O'brien; E M Varga; S J Till; S R Durham; L B Schwartz Journal: J Allergy Clin Immunol Date: 2001-08 Impact factor: 10.793
Authors: Avanika Mahajan; Lama A Youssef; Cédric Cleyrat; Rachel Grattan; Shayna R Lucero; Christopher P Mattison; M Frank Erasmus; Bruna Jacobson; Lydia Tapia; William S Hlavacek; Mark Schuyler; Bridget S Wilson Journal: J Immunol Date: 2016-12-30 Impact factor: 5.422
Authors: Hitendra S Chand; Mark Schuyler; Nancy Joste; Charlene Hensler; Yohannes Tesfaigzi; Barbara Masten; Ron Schrader; Mary F Lipscomb Journal: J Allergy Clin Immunol Date: 2010-03-20 Impact factor: 10.793
Authors: Sarfaraz Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Elizabeth Joyal; Alice Fike; Zerai Manna; Sungyoung Auh; Yinghui Shi; Diana Chan; Philip Carlucci; Ann Biehl; Barbara Dema; Nicolas Charles; James E Balow; Meryl Waldman; Richard M Siegel; Mariana J Kaplan; Juan Rivera Journal: Arthritis Rheumatol Date: 2019-05-08 Impact factor: 10.995